Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.

The Journal of Immunology : Official Journal of the American Association of Immunologists
Lekh N DahalStephen A Beers

Abstract

Rituximab is an anti-CD20 mAb used in the treatment of B cell malignancies. Loss of surface CD20 Ag from the surface of target cells is thought to be one mechanism governing resistance to rituximab, but how this occurs is not completely understood. Two explanations for this have been proposed: antigenic modulation whereby mAb:CD20 complexes are internalized in a B cell intrinsic process and shaving, in which mAb:CD20 complexes undergo trogocytic removal by effector cells, such as macrophages. However, there is conflicting evidence as to which predominates in clinical scenarios and hence the best strategies to overcome resistance. In this study, we investigated the relative importance of modulation and shaving in the downregulation of surface mAb:CD20. We used both murine and human systems and treated ex vivo macrophages with varying concentrations of non-FcγR-interacting beads to achieve differential macrophage saturation states, hence controllably suppressing further phagocytosis of target cells. We then monitored the level and localization of mAb:CD20 using a quenching assay. Suppression of phagocytosis with bead treatment decreased shaving and increased modulation, suggesting that the two compete for surface rituximab:CD20. ...Continue Reading

References

Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Jan 4, 2003·Nature Reviews. Immunology·Siamon Gordon
Feb 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Adam D KennedyRonald P Taylor
Feb 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Paul V BeumRonald P Taylor
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michael E WilliamsRonald P Taylor
Sep 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yongli LiRonald P Taylor
Oct 3, 2007·Blood·Ezogelin OflazogluHans-Peter Gerber
Aug 8, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Paul V BeumRonald P Taylor
Sep 24, 2009·Haematologica·Sean H LimMark S Cragg
Mar 31, 2010·Seminars in Hematology·Ronald P Taylor, Margaret A Lindorfer
Mar 24, 2011·Immunology·Anders E PedersenCharlotte D Pedersen
Aug 16, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Paul V BeumRonald P Taylor
Feb 19, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sarwish RafiqJohn C Byrd
Nov 2, 2013·The Journal of Clinical Investigation·Fabricio MontalvaoPhilippe Bousso
May 27, 2016·Molecular Cancer Therapeutics·Ramraj VelmuruganE Sally Ward
May 12, 2017·Science Translational Medicine·Sean P ArlauckasMikael J Pittet
May 18, 2017·Cancer Research·Lekh N DahalStephen A Beers

❮ Previous
Next ❯

Citations

Jul 23, 2018·Journal of Experimental & Clinical Cancer Research : CR·Michelle H TownsendKim L O'Neill
Dec 9, 2020·Biologicals : Journal of the International Association of Biological Standardization·Kavina ShahVenkat Reddy
Jul 27, 2021·Clinics in Laboratory Medicine·Ting Zhou, Hao-Wei Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.